Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Zhangang Xiao, Jianhua Yin, Fukuan Du, Yuchen Zhang, Chengliang Huang, Yuanlin Wu, Parham Jabbarzadeh Kaboli, Jing Shen, Dandan Yuan, Chi Hin Cho, Xu Wu, Zhuo Zhang, Jing Li, Hanyu Zhang, Yueshui Zhao, Lan Lu, Mingxing Li
Publikováno v:
International Journal of Molecular Medicine
Cluster of differentiation 44 (CD44) as a transmembrane glycoprotein is found to be expressed in non-small cell lung cancer (NSCLC), is significantly associated with NSLC progression, metastasis and drug resistance. This study aimed to explore whethe
Publikováno v:
Molecular Medicine Reports
Aberrant expression of the epidermal growth factor receptor (EGFR) plays vital roles in tumor development and progression. In the present study, ultraviolet irradiation induced the upregulation of EGFR in skin-derived keratinocytes, which may contrib
Autor:
Shuta Tomida, Yu Nakamura, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Tetsuya Mitsudomi, Hiroshi Mizuuchi, Masato Chiba, Kazuto Nishio, Yosuke Togashi, Yoshihiko Fujita, Marco A. De Velasco, Eri Banno
Publikováno v:
International Journal of Oncology
Several receptor tyrosine kinases (RTKs) including EGFR, ALK, and MET have been identified as therapeutic targets in non-small cell lung cancer (NSCLC). Among the downstream pathways of RTKs, the MAPK pathway is particularly important for cancer cell
Autor:
Xing Xing Fan, Betty Yuen Kwan Law, Liang Liu, Paolo Coghi, Vincent Kam Wai Wong, Wu Zeng, Su-Wei Xu, Chung-Hang Leung, Elaine Lai-Han Leung, Dik-Lung Ma, Simon Wing Fai Mok
Publikováno v:
International Journal of Oncology. 49:1576-1588
Drug resistance of non-small cell lung cancer (NSCLC) is highly correlated to the mutation of the epidermal growth factor receptor (EGFR). Although EGFR tyrosine kinase inhibitors (TKIs) are available clinically, the molecular complexity of NSCLC has
Publikováno v:
Molecular Medicine Reports. 14:949-954
MicroRNA (miR)‑27b has been reported to partici-pate in regulating the activity of non‑small cell lung carcinoma (NSCLC) cells. Additionally, when downregulated in NSCLC it promotes resistance to docetaxel; however, the underlying molecular mecha
Autor:
Hong‑Wei Xia, Qiyong Gong, Bi‑Sheng Liu, Qiu‑Lin Tang, Huan‑Ji Xu, Feng Bi, Yong‑Zhan Nie, Xin‑Yu Dai
Publikováno v:
Molecular Medicine Reports.
Dysregulation of epidermal growth factor receptor (EGFR) signaling is responsible for the resistance to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, and is thereby associated with the progression of tumors in non‑small c
Autor:
Concettina La Motta, Francesca Ragusa, Teresa Di Desidero, Ilaria Ruffilli, Simona Piaggi, Guido Bocci, Alessandro Antonelli, Poupak Fallahi, Gabriele Materazzi, Armando Patrizio, Paola Orlandi, Anna Fioravanti, Enke Baldini, Silvia Martina Ferrari, Giusy Elia, Salvatore Ulisse, Paolo Miccoli, Sabrina Rosaria Paparo
Publikováno v:
Oncology Reports.
The antitumor activity of vandetanib [a multiple signal transduction inhibitor including the RET tyrosine kinase, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR), ERK and with antiangiogenic activit
Publikováno v:
Oncology Reports 34(2015)1, 469-476
Epidermal growth factor receptor (EGFR) signaling plays an important role in tumor cell resistance to therapy. In addition to ligand binding, mutual and cooperative interactions of EGFR with integrin cell adhesion receptors critically influence prope
Autor:
Yili Yang, Li-shuang Zhu, Huimin Hu, Jia Chen, Chang Liu, Huiqi Lu, Huabin Yin, Pengfei Zhang, Huanxing Han, Wang Zhou
Publikováno v:
Oncology Reports
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have been used to treat non-small cell lung carcinoma (NSCLC) patients that have EGFR-activating mutations. EGFR-TKI monotherapy in most NSCLC patients with EGFR mutations
Autor:
Xiaoming Liu, Hui-Jing Zhang, Ming-Jun Sun, Lin Guan, Huijuan Ge, Qinghuan Xiao, Xuren Sun, Yining Zhang
Publikováno v:
Oncology Reports. 31:1811-1817
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been used to treat colorectal cancer (CRC). However, resistance to EGFR-TKIs presents a great challenge for the treatment of CRC, and the mechanisms of resistance are poorly